A small pill for massive social impact

Tell us, what does Period Pill do and why?

Period Pill is a biotechnology company developing a novel, first-in-class therapeutic approach for Premenstrual Dysphoric Disorder (PMDD), a severe and under-addressed neuroendocrine condition affecting an estimated 5–8% of menstruating women worldwide.

PMDD is recognized in the DSM-5 and is characterized by severe mood disturbances, depression, and physical complaints that significantly impair daily functioning, mental health, and quality of life. Despite its prevalence and impact, current treatment options remain limited, often poorly tolerated, and insufficiently effective for many patients.

Period Pill was founded to address this major unmet medical need by developing a science-driven, clinically validated treatment aimed at reducing cycle-related mood and pain symptoms, with a strong focus on safety, tolerability, and long-term scalability.

What makes your approach unique?

Period Pill’s innovation lies in a novel, low-dose formulation of a psychoactive compound 3-MMC, specifically to target menstrual cycle-related neuropsychiatric and pain symptoms.

Period Pill has already achieved meaningful scientific and clinical validation. A completed Phase 1 clinical study (find the article in Nature) in collaboration with Maastricht University demonstrated:

• Good safety and tolerability
• A favorable pharmacokinetic profile
• Early signals of beneficial effects on mood and pain perception at low doses

These findings are supported by:

• Early patient observations in PMDD
• Two peer-reviewed scientific publications in Psychopharmacology and Nature
• Broad international patent protection, including method-of-use claims for menstrual cycle-related symptoms

Together, these elements provide a further basis for further clinical development towards a potential first-in-class PMDD therapy. Therefore we are now preparing for a phase 2a clinical trial study.

Which social impact do you strive for?

PMDD places a substantial burden on the women, but also on their relationships, families, workplaces, and the healthcare system. On average it takes 10 years before women get the right diagnosis of PMDD. This means years of doctor and psychologist appointments, misdiagnoses, testing, and using different medicine without the wanted effect. This all while these women suffer every month with depression, physical pain, reduced productivity, strained interpersonal relationships, and elevated risk of severe psychological escalation. 30% of the women with PMDD do a suicide attempt, showing the severe impact on their lives every month.

By delivering a more effective and tolerable treatment option, Period Pill has the potential to:

• Improve quality of life and stability for millions of women
• Reduce workforce absenteeism and productivity loss
• Improve mental health and lower misdiagnoses and secondary healthcare burden
• Contribute to greater social and economic participation of women

The broader societal and economic impact of effective PMDD treatment is therefore significant.

How did you get in touch with TNO Fast Track?

Given the relevance of reproductive health and fertility in the context of menstrual-cycle-related treatments, Period Pill engaged with TNO to conduct an independent scientific screening of potential fertility-related safety risks.

Through a computational toxicology screening and modeling study, TNO evaluated the compound’s potential impact on fertility and reproductive health.

Are you curious if your development question fits TNO Fast Track approach? Take the Quick Scan to find out(opens in a new tab) (refers to another website)(opens in a new tab) (refers to another website) (opens in a new tab) (refers to another website).

This collaboration, through TNO Fast Track, in our experience is very positive. TNO delivers high quality, is fast and thinks with us beyond the question. Exactly what we need in this start-up phase. The outcomes were also positive, so that helped us a lot with derisking the program for phase 2a. For us a great start of a longer collaboration.

Which challenges did TNO help you solve?

The TNO screening - executed by senior toxicologist Hedwig Braakhuis and computational toxicologist Pavel Kostadinov - provided two key contributions:

1. Decision-ready insight: the screening did not indicate receptor-mediated endocrine disruption signals, and it translated the remaining reproductive toxicity uncertainty into concrete next steps (e.g., ICH S5-aligned strategies and relevant OECD assays) to support informed clinical development.
2. Regulatory-relevant guidance: the study delivered clear recommendations on additional safety assessments and development steps for addressing potential fertility risks, supporting Period Pill’s regulatory and clinical roadmap.

This work strengthens Period Pill’s risk-mitigation strategy, particularly given the sensitivity of reproductive health in regulatory, clinical, and public contexts.

The collaboration with TNO has been highly valuable. The credibility of the models and the scientific rigor of the work provided important reassurance and direction for our next development steps.

How do you describe the business relevance of the support you received?

At this stage of development, independent validation, rigorous safety assessment, and credible de-risking are essential for advancing clinical programs and engaging investors, strategic partners, and regulatory stakeholders.

TNO’s contribution strengthens Period Pill’s:

• Scientific and regulatory credibility
• Risk profile and safety narrative
• Investor readiness
• Strategic positioning as a serious, science-driven biotech company

It enables Period Pill to approach the next phase of fundraising and partnerships with a robust, data-backed evidence package supporting both clinical promise and responsible development.

How do you look back at TNOs role?

As highly positive and strategically valuable. The partnership was characterized by scientific rigor, entrepreneurial mindset, and transparent guidance. Kudos to Anna Butter in the TNO Fast Track who supported us.

Looking ahead, Period Pill considers TNO a key potential long-term partner in advancing the scientific, regulatory, and clinical development of its women’s health program, with the shared ambition to build a strong, Dutch-rooted innovation success story with global impact.